Cargando…

Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer

BACKGROUND: Peripheral blood-derived inflammation-based scores such as the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) have recently been proposed as prognostic markers in solid tumours. Although evidence to support these markers as unfavourable prognostic factors is more c...

Descripción completa

Detalles Bibliográficos
Autores principales: Koh, C-H, Bhoo-Pathy, N, Ng, K-L, Jabir, R S, Tan, G-H, See, M-H, Jamaris, S, Taib, N A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647546/
https://www.ncbi.nlm.nih.gov/pubmed/26022929
http://dx.doi.org/10.1038/bjc.2015.183
_version_ 1782401122686730240
author Koh, C-H
Bhoo-Pathy, N
Ng, K-L
Jabir, R S
Tan, G-H
See, M-H
Jamaris, S
Taib, N A
author_facet Koh, C-H
Bhoo-Pathy, N
Ng, K-L
Jabir, R S
Tan, G-H
See, M-H
Jamaris, S
Taib, N A
author_sort Koh, C-H
collection PubMed
description BACKGROUND: Peripheral blood-derived inflammation-based scores such as the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) have recently been proposed as prognostic markers in solid tumours. Although evidence to support these markers as unfavourable prognostic factors is more compelling in gastrointestinal cancers, very little is known of their impact on breast cancer. We investigated the association between the NLR and PLR, and overall survival after breast cancer. METHODS: Data from the University of Malaya Medical Centre Breast Cancer Registry was used. Of 2059 consecutive patients diagnosed from 2000 to 2008, we included 1435 patients with an available pre-treatment differential blood count (∼70%). Patients were stratified into quintiles of the NLR/PLR. Multivariable Cox regression was used to determine the independent prognostic significances of the NLR/PLR. RESULTS: Compared with the first quintile of the NLR, women in quintile 5 were younger, had bigger tumours, nodal involvement, distant metastases and higher tumour grades. Higher NLR quintiles were significantly associated with poorer survival with a 5-year relative survival ratio (RSR) of 76.4% (95% CI: 69.6–82.1%) in quintile 1, 79.4% (95% CI: 74.4–83.7%) in quintile 2, 72.1% (95% CI: 66.3–77.3%) in quintile 3, 65.6% (95% CI: 59.8–70.8%) in quintile 4 and 51.1% (95% CI: 43.3–58.5%) in quintile 5. Following adjustment for demography, tumour characteristics, treatment and the PLR, the adjusted hazard ratio (HR) for quintile 5 vs quintile 1 was 1.50 (95% CI: 1.08–1.63); P(trend)=0.004. Results were unchanged when the NLR was analysed as a dichotomous variable using different cutoff points. Although patients in PLR quintile 5 had lower survival than in quintile 1 (5-year RSR: 53.2% (95% CI: 46.9–59.2%) vs 77.0% (95% CI: 70.9–82.2%)), this association was not significant after multivariable adjustment. However, a PLR >185 was significantly associated with poorer survival; adjusted HR: 1.25 (95% CI: 1.04–1.52). CONCLUSIONS: Both the NLR and PLR are independently associated with an increased risk of mortality in breast cancer. Their added value in the prognostication of breast cancer in clinical practice warrants investigation.
format Online
Article
Text
id pubmed-4647546
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-46475462015-11-17 Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer Koh, C-H Bhoo-Pathy, N Ng, K-L Jabir, R S Tan, G-H See, M-H Jamaris, S Taib, N A Br J Cancer Epidemiology BACKGROUND: Peripheral blood-derived inflammation-based scores such as the neutrophil–lymphocyte ratio (NLR) and platelet–lymphocyte ratio (PLR) have recently been proposed as prognostic markers in solid tumours. Although evidence to support these markers as unfavourable prognostic factors is more compelling in gastrointestinal cancers, very little is known of their impact on breast cancer. We investigated the association between the NLR and PLR, and overall survival after breast cancer. METHODS: Data from the University of Malaya Medical Centre Breast Cancer Registry was used. Of 2059 consecutive patients diagnosed from 2000 to 2008, we included 1435 patients with an available pre-treatment differential blood count (∼70%). Patients were stratified into quintiles of the NLR/PLR. Multivariable Cox regression was used to determine the independent prognostic significances of the NLR/PLR. RESULTS: Compared with the first quintile of the NLR, women in quintile 5 were younger, had bigger tumours, nodal involvement, distant metastases and higher tumour grades. Higher NLR quintiles were significantly associated with poorer survival with a 5-year relative survival ratio (RSR) of 76.4% (95% CI: 69.6–82.1%) in quintile 1, 79.4% (95% CI: 74.4–83.7%) in quintile 2, 72.1% (95% CI: 66.3–77.3%) in quintile 3, 65.6% (95% CI: 59.8–70.8%) in quintile 4 and 51.1% (95% CI: 43.3–58.5%) in quintile 5. Following adjustment for demography, tumour characteristics, treatment and the PLR, the adjusted hazard ratio (HR) for quintile 5 vs quintile 1 was 1.50 (95% CI: 1.08–1.63); P(trend)=0.004. Results were unchanged when the NLR was analysed as a dichotomous variable using different cutoff points. Although patients in PLR quintile 5 had lower survival than in quintile 1 (5-year RSR: 53.2% (95% CI: 46.9–59.2%) vs 77.0% (95% CI: 70.9–82.2%)), this association was not significant after multivariable adjustment. However, a PLR >185 was significantly associated with poorer survival; adjusted HR: 1.25 (95% CI: 1.04–1.52). CONCLUSIONS: Both the NLR and PLR are independently associated with an increased risk of mortality in breast cancer. Their added value in the prognostication of breast cancer in clinical practice warrants investigation. Nature Publishing Group 2015-06-30 2015-05-28 /pmc/articles/PMC4647546/ /pubmed/26022929 http://dx.doi.org/10.1038/bjc.2015.183 Text en Copyright © 2015 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Epidemiology
Koh, C-H
Bhoo-Pathy, N
Ng, K-L
Jabir, R S
Tan, G-H
See, M-H
Jamaris, S
Taib, N A
Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
title Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
title_full Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
title_fullStr Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
title_full_unstemmed Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
title_short Utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
title_sort utility of pre-treatment neutrophil–lymphocyte ratio and platelet–lymphocyte ratio as prognostic factors in breast cancer
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4647546/
https://www.ncbi.nlm.nih.gov/pubmed/26022929
http://dx.doi.org/10.1038/bjc.2015.183
work_keys_str_mv AT kohch utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer
AT bhoopathyn utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer
AT ngkl utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer
AT jabirrs utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer
AT tangh utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer
AT seemh utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer
AT jamariss utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer
AT taibna utilityofpretreatmentneutrophillymphocyteratioandplateletlymphocyteratioasprognosticfactorsinbreastcancer